DocMorris Reports Substantial Earnings Growth and e-Prescription Expansion in Germany for 2023

DocMorris AG announced significant financial achievements and operational milestones for the year 2023, emphasizing a notable improvement in earnings and the integration of e-prescriptions in Germany. The company successfully met its revenue and earnings targets, attributing the success to its break-even program and strategies aimed at sustainable profitability. By enhancing gross margin, productivity, marketing efficiency, and implementing structural cost savings, DocMorris made a considerable leap in its adjusted EBITDA, reducing losses to CHF 34.9 million.

The adoption of fully digital e-prescriptions across Germany marked a pivotal moment for DocMorris, confirming its strategic positioning in the realm of digital healthcare. With over 84,000 medical institutions now part of this initiative, the company is looking forward to leveraging this new standard to further enhance its service offerings. The introduction of the eHealth CardLink, a product enabling mobile management of e-prescriptions, solidifies DocMorris’ commitment to simplifying and securing digital healthcare solutions for patients.

Throughout 2023, DocMorris also focused on enhancing customer experience in specific European markets, leading to improved financial performance in segments like Spain and France. The sale of its Swiss business contributed to reinforcing the company's capital structure, ensuring a robust foundation for continued growth and innovation in the healthcare sector.

Looking ahead, DocMorris projects an upward trend in external revenue growth and anticipates further improvements in adjusted EBITDA for the financial year 2024. Additionally, the company remains dedicated to its sustainability goals, reporting a 13% reduction in CO2 emissions and additional progress in corporate social responsibility initiatives.